应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
GPCR STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD
盘前交易 08-10 09:20:24 EDT
53.14
+0.52
+0.99%
盘前
53.87
+0.73
+1.37%
08:40 EDT
最高
54.80
最低
50.83
成交量
32.95万
今开
53.80
昨收
52.62
日振幅
7.54%
总市值
37.65亿
流通市值
28.66亿
总股本
7,084万
成交额
1,735万
换手率
0.61%
流通股本
5,393万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
Structure Therapeutics宣布，Aleniglipron在2B期试验中显示出长达36周以上最高达16.2%的减重效果
美股速递 · 06-06
Structure Therapeutics宣布，Aleniglipron在2B期试验中显示出长达36周以上最高达16.2%的减重效果
Structure Therapeutics旗下阿伦利普隆展现良好耐受性，停药率仅为10.4%
美股速递 · 06-06
Structure Therapeutics旗下阿伦利普隆展现良好耐受性，停药率仅为10.4%
Structure Therapeutics修订并重述与Leerink Partners及Cantor Fitzgerald的销售协议
美股速递 · 05-08
Structure Therapeutics修订并重述与Leerink Partners及Cantor Fitzgerald的销售协议
Structure Therapeutics将ATM增发规模扩大1.5亿美元 总额达4亿美元
美股速递 · 05-08
Structure Therapeutics将ATM增发规模扩大1.5亿美元 总额达4亿美元
埃诺格鲁肽注射液全国首批处方落地
经济参考网 · 04-27
埃诺格鲁肽注射液全国首批处方落地
Structure Therapeutics任命Matthew Lang为首席运营官兼总法律顾问
投资观察 · 04-15
Structure Therapeutics任命Matthew Lang为首席运营官兼总法律顾问
美股异动 | 礼来(LLY.US)跌超4% 硕迪生物(GPCR.US)实验性减肥药公布积极数据
智通财经 · 03-17
美股异动 | 礼来(LLY.US)跌超4% 硕迪生物(GPCR.US)实验性减肥药公布积极数据
Structure肥胖药物研究结果直追诺和诺德与礼来
格隆汇 · 03-17
Structure肥胖药物研究结果直追诺和诺德与礼来
Structure Therapeutics股价上涨6% 公布实验性肥胖症药物中期试验结果
美股速递 · 03-16
Structure Therapeutics股价上涨6% 公布实验性肥胖症药物中期试验结果
Structure Therapeutics股价逆转走势 披露中期试验结果后盘前大涨13.5%
美股速递 · 03-16
Structure Therapeutics股价逆转走势 披露中期试验结果后盘前大涨13.5%
Structure Therapeutics盘前跌1.6% 披露实验性减肥药中期试验结果
美股速递 · 03-16
Structure Therapeutics盘前跌1.6% 披露实验性减肥药中期试验结果
Structure Therapeutics公司：FDA二期结束会议定于2026年第二季度；三期试验启动计划于2026年下半年推进
美股速递 · 03-16
Structure Therapeutics公司：FDA二期结束会议定于2026年第二季度；三期试验启动计划于2026年下半年推进
Structure Therapeutics中期数据：2.5毫克起始剂量组不良事件相关停药率为2.0%-3.4%
美股速递 · 03-16
Structure Therapeutics中期数据：2.5毫克起始剂量组不良事件相关停药率为2.0%-3.4%
Structure Therapeutics公布每日一次口服小分子GLP-1受体激动剂Aleniglipron二期临床试验积极顶线数据
美股速递 · 03-16
Structure Therapeutics公布每日一次口服小分子GLP-1受体激动剂Aleniglipron二期临床试验积极顶线数据
Structure Therapeutics公司ACCESS OLE研究显示：120毫克剂量在56周内实现持续减重，最高达16.2%
美股速递 · 03-16
Structure Therapeutics公司ACCESS OLE研究显示：120毫克剂量在56周内实现持续减重，最高达16.2%
Structure Therapeutics公布2025年末现金及等价物达14亿美元 预计资金可支撑运营至2028年底
美股速递 · 02-27
Structure Therapeutics公布2025年末现金及等价物达14亿美元 预计资金可支撑运营至2028年底
硕迪生物盘中异动 大幅下挫5.12%报72.09美元
市场透视 · 02-13
硕迪生物盘中异动 大幅下挫5.12%报72.09美元
硕迪生物盘中异动 早盘股价大跌5.11%
市场透视 · 2025-03-10
硕迪生物盘中异动 早盘股价大跌5.11%
异动解读 | 硕迪生物GPCR股价盘中暴跌6.54%,因公司未有利好消息传出
异动解读 · 2025-03-04
异动解读 | 硕迪生物GPCR股价盘中暴跌6.54%,因公司未有利好消息传出
硕迪生物盘中异动 早盘股价大跌5.42%
市场透视 · 2025-03-04
硕迪生物盘中异动 早盘股价大跌5.42%
加载更多
公司概况
公司名称：
STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD
所属市场：
NASDAQ
上市日期：
--
主营业务：
硕迪生物公司于2019年2月在开曼群岛成立，在美国和中国设有运营子公司。该公司是一家临床阶段的全球生物制药公司，旨在开发和提供新型口服疗法，以治疗各种慢性疾病，满足医疗需求。公司的差异化技术平台利用基于结构的药物发现和计算化学专业知识，使公司能够开发口服小分子疗法，用于治疗各种疾病，包括影响代谢、心血管和肺系统的疾病。
发行价格：
--
{"stockData":{"symbol":"GPCR","market":"US","secType":"STK","nameCN":"STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD","latestPrice":53.14,"timestamp":1786132800000,"preClose":52.62,"halted":0,"volume":329495,"hourTrading":{"tag":"盘前","latestPrice":53.87,"preClose":53.14,"latestTime":"08:40 EDT","volume":442,"amount":24112.785788,"timestamp":1786365627294,"change":0.73,"changeRate":0.013737,"amplitude":0.03519},"delay":0,"changeRate":0.009882174078297286,"floatShares":53931500,"shares":70841812,"eps":-3.022893,"marketStatus":"盘前交易","change":0.52,"latestTime":"08-10 09:20:24 EDT","open":53.8,"high":54.8,"low":50.83,"amount":17349835.34181,"amplitude":0.075447,"askPrice":54,"askSize":84,"bidPrice":53,"bidSize":50,"shortable":3,"etf":0,"ttmEps":-3.022893,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1786368600000},"marketStatusCode":1,"adr":0,"adrRate":3,"listingDate":1675400400000,"exchange":"NASDAQ","adjPreClose":53.14,"preHourTrading":{"tag":"盘前","latestPrice":53.87,"preClose":53.14,"latestTime":"08:40 EDT","volume":442,"amount":24112.785788,"timestamp":1786365627294,"change":0.73,"changeRate":0.013737,"amplitude":0.03519},"postHourTrading":{"tag":"盘后","latestPrice":53.74,"preClose":53.14,"latestTime":"19:37 EDT","volume":7947,"amount":422553.5985,"timestamp":1786145833610,"change":0.6,"changeRate":0.011291,"amplitude":0.011291},"volumeRatio":0.6193715283436102,"impliedVol":0.8336,"impliedVolPercentile":0.72},"requestUrl":"/m/hq/s/GPCR","defaultTab":"news","newsList":[{"id":"1180747442","title":"Structure Therapeutics宣布，Aleniglipron在2B期试验中显示出长达36周以上最高达16.2%的减重效果","url":"https://stock-news.laohu8.com/highlight/detail?id=1180747442","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1180747442?lang=zh_cn&edition=full","pubTime":"2026-06-06 04:18","pubTimestamp":1780690711,"startTime":"0","endTime":"0","summary":"Structure Therapeutics Inc. 近日公布了其口服GLP-1受体激动剂Aleniglipron在2B期临床试验中的积极顶线结果。数据显示，在为期36周的治疗期内，接受Aleniglipron治疗的患者实现了显著的体重减轻，最高减重幅度达到16.2%。这项随机、双盲、安慰剂对照的试验评估了不同剂量Aleniglipron在肥胖或超重成人中的疗效与安全性。除了显著的减重数据，Aleniglipron在改善血糖控制等次要终点上也表现出积极趋势。这一积极数据进一步验证了Aleniglipron作为潜在重磅口服减肥疗法的前景。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GPCR","BK4599","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178081119","title":"Structure Therapeutics旗下阿伦利普隆展现良好耐受性，停药率仅为10.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=1178081119","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1178081119?lang=zh_cn&edition=full","pubTime":"2026-06-06 04:18","pubTimestamp":1780690707,"startTime":"0","endTime":"0","summary":"Structure Therapeutics公司宣布，其研发的药物阿伦利普隆在临床试验中表现出良好的耐受性特征，患者停药率低至10.4%。这一数据突显了该药物在治疗过程中的可接受性与安全性，为其进一步的临床开发与应用奠定了积极基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","GPCR","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154055283","title":"Structure Therapeutics修订并重述与Leerink Partners及Cantor Fitzgerald的销售协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1154055283","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154055283?lang=zh_cn&edition=full","pubTime":"2026-05-08 05:17","pubTimestamp":1778188666,"startTime":"0","endTime":"0","summary":"生物制药公司Structure Therapeutics Inc于2026年5月7日向美国证券交易委员会提交文件，宣布与Leerink Partners LLC及Cantor Fitzgerald & Co.共同签署经修订与重述的股权分销协议。该协议旨在优化公司未来通过\"at-the-market\"股权发行计划进行融资的运作框架。此次协议修订涉及分销条款、佣金结构及结算流程等核心商业条款的更新，标志着Structure Therapeutics与两家顶尖医疗健康领域投行深化战略合作的里程碑。通过完善销售协议机制，公司将进一步增强资本运作灵活性，为管线药物研发提供可持续的资金支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GPCR","BK4599","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160867102","title":"Structure Therapeutics将ATM增发规模扩大1.5亿美元 总额达4亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1160867102","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1160867102?lang=zh_cn&edition=full","pubTime":"2026-05-08 05:17","pubTimestamp":1778188634,"startTime":"0","endTime":"0","summary":"生物医药公司Structure Therapeutics Inc（股票代码：GPCR）近日向美国证券交易委员会提交文件，宣布将其ATM（按市价发行）股票增发计划规模扩大1.5亿美元。此次调整后，该公司的ATM增发总规模将达到4亿美元。\nATM增发机制允许上市公司在特定时期内，根据市场情况灵活地向公众发售新股。此次规模扩充将为Structure Therapeutics提供更充足的资金流动性，支持其临床阶段药物研发管线的推进。该公司专注于开发针对代谢性疾病的口服小分子疗法，此次融资安排彰显了其持续优化资本结构的战略布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GPCR","BK4599","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630391708","title":"埃诺格鲁肽注射液全国首批处方落地","url":"https://stock-news.laohu8.com/highlight/detail?id=2630391708","media":"经济参考网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2630391708?lang=zh_cn&edition=full","pubTime":"2026-04-27 20:50","pubTimestamp":1777294212,"startTime":"0","endTime":"0","summary":"4月27日，新一代cAMP偏向型GLP-1受体激动剂埃诺格鲁肽注射液（先维盈）在北京大学人民医院与复旦大学附属中山医院同步开出全国首批处方，标志着这款创新体重管理疗法正式在中国迈入临床应用阶段。据悉，GLP-1受体激动剂的创新研发有两条路线。传统路线是以GLP-1为核心靶点叠加其他作用靶点，如GIP、GCG等。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604273720616957.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604273720616957.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4007","BK4599","GPCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115849765","title":"Structure Therapeutics任命Matthew Lang为首席运营官兼总法律顾问","url":"https://stock-news.laohu8.com/highlight/detail?id=1115849765","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1115849765?lang=zh_cn&edition=full","pubTime":"2026-04-15 04:07","pubTimestamp":1776197275,"startTime":"0","endTime":"0","summary":"旧金山，2026年4月14日——临床阶段全球生物制药公司Structure Therapeutics Inc.今日宣布，任命Matthew Lang, J.D. 为公司首席运营官兼总法律顾问。Lang先生在加入Structure Therapeutics时，已在全球生物制药机构拥有超过十五年的高管领导经验，其深厚专长涵盖法律、企业战略、合规、风险管理和业务发展等多个领域。Structure Therapeutics首席执行官Raymond Stevens博士表示：\"Matt是一位经验丰富的领导者，在引导组织实现增长和转型方面拥有卓越的业绩记录。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","BK4139","GPCR","BK4007","BK4022","R","BK4599","BK4539","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620476982","title":"美股异动 | 礼来(LLY.US)跌超4% 硕迪生物(GPCR.US)实验性减肥药公布积极数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2620476982","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2620476982?lang=zh_cn&edition=full","pubTime":"2026-03-17 23:14","pubTimestamp":1773760452,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周二，礼来(LLY.US)股价低开低走，截至发稿，该股跌超4%，报948.76美元。消息面上，硕迪生物(GPCR.US)此前公布其实验性减肥药aleniglipron积极结果。数据显示，患者在服用44周后，体重减轻了约15%。BMO资本市场分析师Evan Seigerman指出，该药物的疗效“看起来极具竞争力”，甚至可能优于诺和诺德(NVO.US)和礼来的同类口服药。硕迪生物计划在2026年下半年启动后期研究，采用“低量且缓慢”的剂量滴定法以预防胃肠道副作用。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1415150.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1551013425.SGD","LU0882574055.USD","IE00BKPKM429.USD","LU2168564065.EUR","LU0256863811.USD","LU0640476718.USD","LU1291159041.SGD","LU2602419157.SGD","LU1232071149.USD","LU2237443549.SGD","LU0109391861.USD","LU0323591593.USD","SG9999001176.USD","LU2265009873.SGD","IE00BJJMRY28.SGD","LU0122379950.USD","LU2023250504.SGD","LU1868837300.USD","LU2089984988.USD","LU0006306889.USD","LU1720051108.HKD","LU1127390331.HKD","LU2028103732.USD","IE00B7KXQ091.USD","LU0096364046.USD","LU1035775433.USD","LU0109394709.USD","LU0820562030.AUD","IE00BN29S564.USD","LU0432979614.USD","LU0672654240.SGD","LU0203201768.USD","LU0823416689.USD","LU2237443895.HKD","LU2756315664.SGD","LU0889565916.HKD","LU1366192091.USD","LU2896262040.SGD","LU0210536198.USD","LU1868836914.USD","LU1548497426.USD","GPCR","SGXZ57979304.SGD","LLYZ","BK4581","LU1323610961.USD","LLY","SG9999015978.USD","LU0079474960.USD","LU2108987350.USD","LU1868836757.USD","LU0320765059.SGD","LU0058720904.USD","LU1267930730.SGD","SG9999015945.SGD","IE00B1BXHZ80.USD","LU1069344957.HKD","LU0417517546.SGD","LU1814569148.SGD","LU2471134952.CNY","IE00B4JS1V06.HKD","LU2746668974.SGD","SG9999013999.USD","LU2168564149.EUR","IE00BKDWB100.SGD","LU2462157665.USD","SG9999015952.SGD","BK4533","IE0005OL40V9.USD","LU0354030438.USD","LU2237438978.USD","LU0964807845.USD","LU2552382058.USD","LU2750360641.GBP","IE00BJLML261.HKD","LU2106854487.HKD","LLYX","LU2750360997.AUD","LU0234572021.USD","IE00BJJMRZ35.SGD","LU0683600562.USD","LU2271345857.HKD","IE00BFSS7M15.SGD","LU2168564495.EUR","SG9999018865.SGD","LU0320765992.SGD","LU0708995401.HKD","SG9999014898.SGD","LU2360106947.USD","LU0158827948.USD","LU1064131342.USD","LU0203202063.USD","LU2361044949.HKD","LU1057294990.SGD","IE00BWXC8680.SGD","LU0689472784.USD","BK4007","LU2023251221.USD","LU2111349929.HKD","LU2089284900.SGD","LU2756315318.SGD","IE0004445239.USD","LU0061475181.USD","LU2237443622.USD","LU0106261372.USD","LU1145028129.USD","LU0882574139.USD","IE00BFTCPJ56.SGD","LU0456855351.SGD","LU2471134879.HKD","LU2087625088.SGD","SGXZ31699556.SGD","BK4599","LU0823434583.USD","SG9999014914.USD","ELIL","LU1989771016.USD","LU0353189763.USD","SGXZ51526630.SGD","LU2237443465.HKD","LU1720051017.SGD","LU0354030511.USD","IE0002141913.USD","LU0820561818.USD","LU1983299246.USD","LU0289739699.SGD","LU2491050071.SGD","LU2237443978.SGD","LU1988902786.USD","LU1868836591.USD","LU2357305700.SGD","SG9999015986.USD","SG9999014880.SGD","SGXZ99366536.SGD","IE00B1XK9C88.USD","LU1868837136.USD","LU2264538146.SGD","LU0238689110.USD","LU1280957306.USD","LU1551013342.USD","LU0097036916.USD","LU1093756168.USD","LU0353189680.USD","SG9999017495.SGD","GB00BDT5M118.USD","LU0466842654.USD","IE00BK4W5L77.USD","LU0266013472.USD","LU0316494557.USD","SG9999018857.SGD","IE0004445015.USD","LU2471134523.USD","BK4534","LU0256863902.USD","LU1804176565.USD","LU2211815571.USD","LU2417539215.USD","LU1061106388.HKD","LU2023250330.USD","IE00BK4W5M84.HKD","LU2456880835.USD","LU2089283258.USD","LU0471298694.HKD","LU0385154629.USD","LU2213496289.HKD","LU0094547139.USD","LU2168564222.USD","BK4585","LU0820561909.HKD","LU0114720955.EUR","IE00B4R5TH58.HKD","LU0225283273.USD","LU0823434740.USD","LU1623119135.USD","LU1974910355.USD","LU2324357040.USD","LU1629891620.HKD","LU2471134796.USD","IE00BJT1NW94.SGD","IE0009355771.USD","LU2236285917.USD","LLII","LU2063271972.USD","LU2552382215.SGD","IE0001KFT4U8.USD","LU2361044865.SGD","LU2237443382.USD","BK4516","LU2461242641.AUD","SGXZ81514606.USD","LU1023059063.AUD","LU1093756325.SGD","IE00BJJMRX11.SGD","LU2491050154.USD","SG9999014906.USD","IE00BFSS8Q28.SGD","IE00B2B36J28.USD","LU2168563687.JPY","SG9999001176.SGD","LU1712237335.SGD","LU0786609619.USD","BK4588","LU2112291526.USD","LU2468319806.SGD","LU2746668461.USD","IE00B775H168.HKD","LU0787776722.HKD","LU0471298777.SGD","LU0158827781.USD","LU2491049909.HKD","LU2361045086.USD","LU1917777945.USD","LU2552382132.HKD","LU0943347566.SGD","ELIS","LU0198837287.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620476890","title":"Structure肥胖药物研究结果直追诺和诺德与礼来","url":"https://stock-news.laohu8.com/highlight/detail?id=2620476890","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2620476890?lang=zh_cn&edition=full","pubTime":"2026-03-17 23:08","pubTimestamp":1773760090,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU0122379950.USD","LU2417539215.USD","LU2168564149.EUR","LU2552382058.USD","LU2462157665.USD","LLYX","LU2112291526.USD","LU0210536198.USD","LU0154236417.USD","LU1023059063.AUD","LU0823434740.USD","LU2471134879.HKD","LU0320765059.SGD","LU2023250504.SGD","LU0203202063.USD","SGXZ81514606.USD","LU1868836757.USD","LU2756315664.SGD","LU0823416689.USD","LU2491050071.SGD","LU2746668974.SGD","LU1868837300.USD","IE00BKDWB100.SGD","LU1804176565.USD","LU1267930730.SGD","LU2552382215.SGD","NVOX","SGXZ57979304.SGD","LU0289739699.SGD","IE00B1BXHZ80.USD","IE00B1XK9C88.USD","LU0256863811.USD","LU0266013472.USD","ELIS","LU1366192091.USD","LU0158827948.USD","LU2108987350.USD","LU2361044949.HKD","IE00BFSS8Q28.SGD","SG9999013999.USD","SG9999015945.SGD","BK4534","SG9999014880.SGD","LU0471298777.SGD","LU2237443549.SGD","LU2552382132.HKD","LU1093756325.SGD","LU2023251221.USD","BK4585","LU0882574139.USD","LU1814569148.SGD","LU2168564495.EUR","LU0466842654.USD","LU1974910355.USD","IE0002141913.USD","LU1868836591.USD","IE00B7KXQ091.USD","LU0385154629.USD","IE0004445015.USD","LU0238689110.USD","LU1280957306.USD","LU0672654240.SGD","LU2264538146.SGD","LU0882574055.USD","LU2746668461.USD","LU2491049909.HKD","LU0114720955.EUR","LU0964807845.USD","LU2111349929.HKD","LU0323591593.USD","GPCR","LU0823434583.USD","IE0004445239.USD","LU1145028129.USD","IE00BJLML261.HKD","LU0203201768.USD","LU1720051108.HKD","BK4516","SG9999015978.USD","SG9999014898.SGD","LU1551013425.SGD","BK4007","IE00BN29S564.USD","LU0943347566.SGD","LU1988902786.USD","LU1093756168.USD","IE00BFSS7M15.SGD","LU1069344957.HKD","SG9999018865.SGD","LU0256863902.USD","BK4533","LU2237443978.SGD","LU0689472784.USD","IE00BK4W5M84.HKD","LU1983299246.USD","LU0417517546.SGD","BK4532","GB00BDT5M118.USD","IE00BFTCPJ56.SGD","LU0320765992.SGD","IE00BJJMRY28.SGD","LU0820561909.HKD","LU2461242641.AUD","LU2750360641.GBP","LU2028103732.USD","LU2237443622.USD","IE0009355771.USD","LU0353189763.USD","SG9999015952.SGD","LU2087625088.SGD","IE00B2B36J28.USD","LU0316494557.USD","LU2471134523.USD","LU0225283273.USD","LU1127390331.HKD","LU2265009873.SGD","IE00B4R5TH58.HKD","LU2211815571.USD","LU0432979614.USD","SG9999014906.USD","LU0683600562.USD","LU2168564065.EUR","BK4581","LU0094547139.USD","LU2271345857.HKD","LU2471134952.CNY","LU0006306889.USD","LU2089283258.USD","LU0787776722.HKD","LU2602419157.SGD","LU0198837287.USD","LU2236285917.USD","LU2360106947.USD","IE00B4JS1V06.HKD","LU1035775433.USD","LU1868836914.USD","LU0889565916.HKD","LU0786609619.USD","LU2324357040.USD","LU1232071149.USD","LLII","LU2237438978.USD","LU0058720904.USD","LU1623119135.USD","LU1712237335.SGD","IE00BKVL7J92.USD","SG9999001176.SGD","LU2491050154.USD","LU1720051017.SGD","IE00BKPKM429.USD","LU2168564222.USD","LU2237443895.HKD","LU2471134796.USD","LU1061106388.HKD","IE00BJJMRX11.SGD","LU1323610961.USD","NVOH","LU0109394709.USD","IE00BJJMRZ35.SGD","IE00BZ1G4Q59.USD","LU0354030438.USD","LU2750360997.AUD","SGXZ31699556.SGD","LU0097036916.USD","IE00BJT1NW94.SGD","LU0353189680.USD","SG9999015986.USD","SG9999014914.USD","LU0820561818.USD","BK4599","LU1551013342.USD","LU2357305700.SGD","LU2237443382.USD","LU0234572021.USD","LU0079474960.USD","SG9999018857.SGD","LU2089984988.USD","LU0109391861.USD","LU1917777945.USD","LU1291159041.SGD","LU2023250330.USD","LU0354030511.USD","LU1548497426.USD","IE00BWXC8680.SGD","LU0708995401.HKD","LU2089284900.SGD","LU2168563687.JPY","LU2361045086.USD","LU2756315318.SGD","BK4588","LU2237443465.HKD","SGXZ99366536.SGD","LU1868837136.USD","LU0820562030.AUD","LU1064131342.USD","LU0640476718.USD","LU2063271972.USD","ELIL","LU0158827781.USD","LU0456855351.SGD","LLYZ","IE00B775H168.HKD","SG9999017495.SGD","LU1629891620.HKD","IE0001KFT4U8.USD","LU1989771016.USD","LU0471298694.HKD","SG9999001176.USD","LU2106854487.HKD","LU2213496289.HKD","LU2361044865.SGD","IE00BK4W5L77.USD","LU0061475181.USD","IE0005OL40V9.USD","LU2896262040.SGD","LU2456880835.USD","SGXZ51526630.SGD","LU2468319806.SGD","LU1057294990.SGD","LU0096364046.USD","LU0106261372.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140362721","title":"Structure Therapeutics股价上涨6% 公布实验性肥胖症药物中期试验结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1140362721","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1140362721?lang=zh_cn&edition=full","pubTime":"2026-03-16 21:32","pubTimestamp":1773667958,"startTime":"0","endTime":"0","summary":"在披露其实验性口服肥胖症药物的中期临床试验数据后，Structure Therapeutics Inc.（股票代码：GPCR）股价今日上涨6%。\n该公司公布的第二阶段研究结果显示，其口服GLP-1受体激动剂GSBR-1292在12周治疗期内展现出显著的减重效果。接受治疗的患者平均体重下降幅度达统计学意义，且药物耐受性良好，未出现严重不良反应。\n这一积极数据令投资者对该公司挑战诺和诺德、礼来等制药巨头的口服减肥药市场前景感到乐观。分析师指出，若后续临床试验继续验证其疗效与安全性，该药物有望成为肥胖症治疗领域的重要竞争者。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4599","GPCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134097930","title":"Structure Therapeutics股价逆转走势 披露中期试验结果后盘前大涨13.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1134097930","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1134097930?lang=zh_cn&edition=full","pubTime":"2026-03-16 19:24","pubTimestamp":1773660253,"startTime":"0","endTime":"0","summary":"在公布其实验性肥胖症药物的中期临床试验结果后，Structure Therapeutics的股价出现显著逆转。该股在盘前交易中一度飙升13.5%，扭转了此前的下跌趋势。\n此次披露的积极数据主要涉及公司研发的口服肥胖症疗法，该疗法在中期试验中达到了主要终点和关键次要终点，显示出显著的减重效果和良好的安全性特征。这一利好消息提振了投资者信心，推动股价强势反弹。\n市场分析师认为，这一进展不仅验证了该药物的潜力，也为Structure Therapeutics在竞争激烈的减肥药市场中赢得了重要地位。随着肥胖症治疗需求的持续增长，该公司的未来发展前景备受关注。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GPCR","BK4599","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160730772","title":"Structure Therapeutics盘前跌1.6% 披露实验性减肥药中期试验结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1160730772","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1160730772?lang=zh_cn&edition=full","pubTime":"2026-03-16 19:11","pubTimestamp":1773659469,"startTime":"0","endTime":"0","summary":"在公布其实验性口服减肥药物的中期临床试验数据后，生物制药公司Structure Therapeutics的股价在盘前交易时段下跌1.6%。此次下跌反映了市场对该阶段性成果的初步反应。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GPCR","BK4599","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175317698","title":"Structure Therapeutics公司：FDA二期结束会议定于2026年第二季度；三期试验启动计划于2026年下半年推进","url":"https://stock-news.laohu8.com/highlight/detail?id=1175317698","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1175317698?lang=zh_cn&edition=full","pubTime":"2026-03-16 19:04","pubTimestamp":1773659040,"startTime":"0","endTime":"0","summary":"Structure Therapeutics公司宣布，其与美国食品药品监督管理局（FDA）的二期临床试验结束会议已正式安排在2026年第二季度举行。此次会议旨在讨论二期试验数据，并为后续的三期临床试验方案提供指导。\n与此同时，公司确认其三期临床试验的启动计划仍按原定时间表推进，预计将在2026年下半年开始。这一进展标志着公司在核心研发项目上迈出了关键一步，为其主要候选药物的未来发展奠定了重要基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4599","GPCR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144091293","title":"Structure Therapeutics中期数据：2.5毫克起始剂量组不良事件相关停药率为2.0%-3.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=1144091293","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1144091293?lang=zh_cn&edition=full","pubTime":"2026-03-16 19:03","pubTimestamp":1773659032,"startTime":"0","endTime":"0","summary":"STRUCTURE THERAPEUTICS INC最新公布的中期临床试验数据显示，采用2.5毫克起始剂量的治疗组中，因不良事件导致停药的发生率介于2.0%至3.4%之间。这一关键指标为评估该药物安全性提供了重要参考。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GPCR","BK4007","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120934691","title":"Structure Therapeutics公布每日一次口服小分子GLP-1受体激动剂Aleniglipron二期临床试验积极顶线数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1120934691","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120934691?lang=zh_cn&edition=full","pubTime":"2026-03-16 19:01","pubTimestamp":1773658905,"startTime":"0","endTime":"0","summary":"STRUCTURE THERAPEUTICS INC（股票代码：GPCR）近日宣布，其研发的每日一次口服小分子GLP-1受体激动剂Aleniglipron，在二期ACCESS II临床试验中取得了积极的顶线数据。这一突破性进展标志着公司在代谢性疾病治疗领域迈出了重要一步。\n临床试验结果显示，Aleniglipron在有效性和安全性方面均表现出色，为后续研发奠定了坚实基础。该药物若成功上市，有望为全球数百万糖尿病患者提供更便捷的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GPCR","BK4007","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173154837","title":"Structure Therapeutics公司ACCESS OLE研究显示：120毫克剂量在56周内实现持续减重，最高达16.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=1173154837","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1173154837?lang=zh_cn&edition=full","pubTime":"2026-03-16 19:01","pubTimestamp":1773658874,"startTime":"0","endTime":"0","summary":"Structure Therapeutics公司最新公布的ACCESS OLE研究数据揭示，其研发的120毫克剂量药物在56周的治疗周期内展现出显著的持续减重效果，患者体重减轻幅度最高可达16.2%。这一结果进一步验证了该药物在体重管理领域的潜在疗效。\n研究数据显示，随着治疗时间的延长，药物的减重效果呈现持续改善的趋势。至56周时，接受120毫克剂量治疗的患者群体实现了平均体重的大幅下降，凸显了该疗法在长期体重控制中的积极作用。\n此次公布的OLE研究结果为公司后续的临床开发及商业化策略提供了重要的数据支持，也为肥胖症患者带来了新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GPCR","BK4007","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148781980","title":"Structure Therapeutics公布2025年末现金及等价物达14亿美元 预计资金可支撑运营至2028年底","url":"https://stock-news.laohu8.com/highlight/detail?id=1148781980","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1148781980?lang=zh_cn&edition=full","pubTime":"2026-02-27 05:30","pubTimestamp":1772141412,"startTime":"0","endTime":"0","summary":"生物制药企业Structure Therapeutics近日披露，截至2025年12月31日，公司持有的现金及现金等价物规模达14亿美元。这一资金储备预计将为公司现有研发及运营计划提供充足支持，现金流可延续至2028年末。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4599","GPCR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2611698391","title":"硕迪生物盘中异动 大幅下挫5.12%报72.09美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2611698391","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2611698391?lang=zh_cn&edition=full","pubTime":"2026-02-13 04:59","pubTimestamp":1770929957,"startTime":"0","endTime":"0","summary":"北京时间2026年02月13日04时59分，硕迪生物股票出现异动，股价急速跳水5.12%。截至发稿，该股报72.09美元/股，成交量42.8565万股，换手率0.61%，振幅6.59%。机构评级方面，在所有16家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。硕迪生物股票所在的生物技术行业中，整体涨幅为0.25%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260213045917a6f4a6c1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260213045917a6f4a6c1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4599","GPCR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518865271","title":"硕迪生物盘中异动 早盘股价大跌5.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518865271","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518865271?lang=zh_cn&edition=full","pubTime":"2025-03-10 22:28","pubTimestamp":1741616909,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日22时28分，硕迪生物股票出现波动，股价大幅跳水5.11%。截至发稿，该股报21.47美元/股，成交量6.4194万股，换手率0.11%，振幅3.80%。机构评级方面，在所有13家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。硕迪生物股票所在的生物技术行业中，整体涨幅为0.40%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310222829a26a3aa9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310222829a26a3aa9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GPCR","BK4599","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148740425","title":"异动解读 | 硕迪生物GPCR股价盘中暴跌6.54%,因公司未有利好消息传出","url":"https://stock-news.laohu8.com/highlight/detail?id=1148740425","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1148740425?lang=zh_cn&edition=full","pubTime":"2025-03-04 23:28","pubTimestamp":1741102110,"startTime":"0","endTime":"0","summary":"硕迪生物(GPCR.US)股价今日盘中大跌6.54%,引发市场关注。\n\n从公开消息来看,硕迪生物是一家临床阶段的生物制药公司,主要产品为治疗糖尿病和肥胖症的口服候选药物GSBR-1290。但就目前来看,该公司并未传出任何重大利好消息,导致投资者对公司前景缺乏信心,加之部分资金选择了获利了结,因此可能是造成股价大跌的主要原因。\n\n不过值得注意的是,该股近期财务数据良好,去年全年虽然净亏损达1.23亿美元,但营收有望在新药上市后显著改善。另外机构给予的评级均为买入,显示出对公司长期前景的乐观预期。因此,只要公司研发顺利,未来随着新药问世,股价或将迎来反弹。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"异动解读 | 硕迪生物GPCR股价盘中暴跌6.54%,因公司未有利好消息传出","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["GPCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516714608","title":"硕迪生物盘中异动 早盘股价大跌5.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516714608","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516714608?lang=zh_cn&edition=full","pubTime":"2025-03-04 23:19","pubTimestamp":1741101575,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日23时19分，硕迪生物股票出现波动，股价快速下挫5.42%。截至发稿，该股报21.13美元/股，成交量10.8238万股，换手率0.19%，振幅4.89%。机构评级方面，在所有12家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。硕迪生物股票所在的生物技术行业中，整体涨幅为0.43%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304231935a25f1345&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304231935a25f1345&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GPCR","BK4007","BK4599"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.structuretx.com","stockEarnings":[{"period":"1week","weight":0.1062},{"period":"1month","weight":-0.0319},{"period":"3month","weight":0.3591},{"period":"6month","weight":-0.2907},{"period":"1year","weight":2.2802},{"period":"ytd","weight":-0.2359}],"compareEarnings":[{"period":"1week","weight":0.0351},{"period":"1month","weight":0.0374},{"period":"3month","weight":0.0483},{"period":"6month","weight":0.1197},{"period":"1year","weight":0.223},{"period":"ytd","weight":0.1339}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"硕迪生物公司于2019年2月在开曼群岛成立，在美国和中国设有运营子公司。该公司是一家临床阶段的全球生物制药公司，旨在开发和提供新型口服疗法，以治疗各种慢性疾病，满足医疗需求。公司的差异化技术平台利用基于结构的药物发现和计算化学专业知识，使公司能够开发口服小分子疗法，用于治疗各种疾病，包括影响代谢、心血管和肺系统的疾病。","yearOnYearQuotes":[{"month":1,"riseRate":1,"avgChangeRate":0.149001},{"month":2,"riseRate":0,"avgChangeRate":-0.188474},{"month":3,"riseRate":0.25,"avgChangeRate":-0.12966},{"month":4,"riseRate":0.5,"avgChangeRate":0.102223},{"month":5,"riseRate":0.25,"avgChangeRate":-0.029871},{"month":6,"riseRate":0.75,"avgChangeRate":0.191173},{"month":7,"riseRate":0,"avgChangeRate":-0.102138},{"month":8,"riseRate":0.75,"avgChangeRate":-0.006092},{"month":9,"riseRate":1,"avgChangeRate":0.463472},{"month":10,"riseRate":0.666667,"avgChangeRate":0.200398},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.123384},{"month":12,"riseRate":0.333333,"avgChangeRate":0.164068}],"exchange":"NASDAQ","name":"STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD","nameEN":"STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD(GPCR)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD(GPCR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD,GPCR,STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD股票,STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD股票老虎,STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD股票老虎国际,STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD行情,STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD股票行情,STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD股价,STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD股市,STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD股票价格,STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD股票交易,STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD股票购买,STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD(GPCR)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD(GPCR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}